RE: Previous Eric leire interview.29 May 2026 08:01
this is why genflow is a superb investment.
lon:genf) chief executive officer dr. eric leire caught up with ************* to discuss recent progress, funding, market opportunities, and upcoming catalysts.
q1: some incredible progress and achievements made over the last 6 to 12 months. eric, what were the key highlights for you?
a1: i would especially like to focus on the dog study, animal health, where the ongoing clinical trial is moving according to the plan, with now the recent publication of interim results that were very promising.
second, we moved to an ophthalmic programme with the ambition to change the way we treat glaucoma. glaucoma now is treated as a pathology of the high pressure in the eye, but the real problem is the degeneration of the retina, so your posterior part of the eye and the beginning of the nerve. we have here some preliminary data that are extremely exciting. we can revolutionise the way we treat glaucoma.
i will not forget that we got some good progress in sarcopenia, and also, we are moving very comfortably with the transition from aavs to now an mrna lnp platform.
it’s all very positive.
q2: you recently announced successful funding and a €4 million grant. what will that funding be used for?
a2: that’s part of the excitement for 2025. it was a successful year. we secured the mash grant that will cover €4 million, so that’s a significant addition in terms of non-dilutive grants. it’s coming in addition to the grant we have for the sarcopenia programme and for the ‘exofastrack’ programme. so, we have now three grants that are funding the company.
in addition to that, we did also a nice series of little fundraising, classical fundraising, non-dilutive with historical shareholders.
q3: what can you tell me about the size of the markets that you were targeting?
a3: that’s one part of the company that we don’t communicate enough.
one of the appeals of genflow biosciences is the fact that we’re targeting very large market opportunities. when i say large market opportunities, i’m not talking only about the number of patients we could treat, but also the size of the unmet need that allow us to have some very attractive pricing opportunity.
for mash – metabolic dysfunction-associated steatohepatitis – for example, we target a segment of the market. the early stage of mash is relatively well covered with glp-1 and a product from madrigal, resmetirom. we are more interested in the late stage when the mash has really evolved towards cirrhosis and risk of hepatocarcinoma. here, we only compete against liver transplantation. very expensive, very difficult, a lot of logistical problems. so, very nice competitor to compete with. it’s still a very large market opportunity. this segment is one third of mash, mash being more than 30 to 40 million people based on different estimations in the world.
related news: genflow biosciences (lon:genf) and the breakthrough promise of gene therapy in chil
Sign In
Follow the stocks
